Skip to main content

Adaptimmune Therapeutics PLC

ADAPY
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001621227

No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Adaptimmune Therapeutics PLC changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of ADAPY: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders8482−2
Shares117.5M111.7M−5.81M (−4.9%)
Value$623.8M$475.7M−$148.1M (−23.7%)

New holders (10)

Institutions that held Adaptimmune Therapeutics PLC at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to ADAPY in Q2 2021
InstitutionSharesValue% of portfolio
Jump Financial, LLC128,200$546.0K0.05%
HRT Financial LP42,621$181.0K0.00%
Credit Agricole S A30,000$128.0K0.00%
HighTower Advisors, LLC15,000$64.0K0.00%
Sigma Planning Corp10,209$43.0K0.00%
Itau Unibanco Holding S.A.8,892$38.0K0.00%
Brewin Dolphin Ltd7,050$30.0K0.00%
Vectors Research Management, LLC4,000$17.0K0.00%
State of Wyoming825$4.00K0.00%
Advisor Group Holdings, Inc.50$00.00%

Sold out (12)

Institutions that held Adaptimmune Therapeutics PLC at the end of Q1 2021 and filed for Q2 2021 without it.